Search hospitals > Idaho > Coeur D Alene
Beacon Cancer Care
Claim this profileCoeur D Alene, Idaho 83814
Conducts research for Squamous Cell Carcinoma
Conducts research for Cancer
Conducts research for Follicular Lymphoma
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
9 reported clinical trials
1 medical researcher
Summary
Beacon Cancer Care is a medical facility located in Coeur D Alene, Idaho. This center is recognized for care of Squamous Cell Carcinoma, Cancer, Follicular Lymphoma, Lymphoma, Pancreatic Cancer and other specialties. Beacon Cancer Care is involved with conducting 9 clinical trials across 21 conditions. There are 1 research doctors associated with this hospital, such as Danko Martincic, MD.Area of expertise
1Squamous Cell Carcinoma
Stage IV
p16 positive
p16 negative
2Cancer
Stage IV
Stage III
Top PIs
Clinical Trials running at Beacon Cancer Care
Follicular Lymphoma
Lymphoma
Pancreatic Cancer
Adenocarcinoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Epcoritamab + Rituximab + Lenalidomide
for Lymphoma
This trial tests a new drug combination for adults with untreated follicular lymphoma, a type of blood cancer. The new treatment includes epcoritamab, lenalidomide, and rituximab, which work together to help the immune system attack cancer cells. The study will check how safe and effective this combination is. Lenalidomide combined with rituximab has shown high efficacy in both relapsed/refractory and untreated follicular lymphoma.
Recruiting2 awards Phase 310 criteria
Epcoritamab
for Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL). Adverse events will be assessed. Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R FL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab. Participants will receive escalating doses of epcoritamab, until full dose is achieved. Approximately 184 adult participants with R/R DLBCL and R/R FL will be enrolled in the study in approximately 80 sites in the United States of America. Participants will receive escalating doses of subcutaneous epcoritamab, until full dose is achieved, in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Recruiting1 award Phase 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Beacon Cancer Care?
Beacon Cancer Care is a medical facility located in Coeur D Alene, Idaho. This center is recognized for care of Squamous Cell Carcinoma, Cancer, Follicular Lymphoma, Lymphoma, Pancreatic Cancer and other specialties. Beacon Cancer Care is involved with conducting 9 clinical trials across 21 conditions. There are 1 research doctors associated with this hospital, such as Danko Martincic, MD.